Skip to main content
. Author manuscript; available in PMC: 2015 Feb 19.
Published in final edited form as: Cancer Res. 2013 Apr 22;73(9):2743–2748. doi: 10.1158/0008-5472.CAN-12-4183

Figure 1. Differential impact of sunitinib or pazopanib monotherapy on primary tumor growth versus postsurgical advanced metastatic breast cancer.

Figure 1

Sunitinib administered daily inhibits primary tumor growth (Fig. 1A), but has no survival benefit when treating advanced metastatic disease (Fig. 1B). The lower panel shows similar results with pazopanib administered daily (Figs. 1C and 1D). For Figs. 1A and B, 2x106 MDA-MB 231/LM2-4 cells were implanted into the mammary fat pad of 6 CB-17 SCID female mice; in the primary tumor study, treatment with sunitinib was initiated 12 days later when average tumor size was 100mm3; in the advanced metastasis therapy study, primary tumors were surgically resected 20 days after cell injection when average size was approximately 400mm3 and sunitinib treatment was initiated 21 days later.

For Figs. 1C and 1D, 2x106 MDA-MB 231/LM2-4 cells were implanted in the primary tumor study (Fig. 1C) pazopanib treatment was initiated 14 days later when average tumor size was 150mm3; in the advanced metastasis therapy study (Fig. 1D), the primary tumors were surgically resected 20 days after cell injection when average size was approximately 400mm3 and treatment was initiated 19 days later.